After unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019, and allowed DNL to revise the primary endpoint in the protocol for the US Phase III trial.
The seller and rights issue were the reasons this sp reduced two thirds and with short selling to compile. Is the company stronger and in a better place now, yes imo.